FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and concerns stabilized aqueous compositions of recombinant furine, wherein compositions contain recombinant furine, pharmaceutically acceptable salt, calcium, sugar or sugar alcohol, non-ionic surfactant and buffer substance.
EFFECT: group of inventions provides preserving more furine activity and content of monomer furine at simultaneous reduction of aggregation during storage and/or action of mechanical load.
42 cl, 49 dwg, 22 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNF-α | 2017 |
|
RU2764521C2 |
| ANTIBODY AND PROTEIN COMPOSITIONS | 2013 |
|
RU2678097C2 |
| RECOMBINANT MONOCLONAL ANTIBODY TO TNF-ALPHA AQUEOUS PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2665966C2 |
| SUSTAINED TYPE HUMAN GROWTH HORMONE PREPARATION | 2014 |
|
RU2683823C2 |
| PREPARATIONS OF ANTIBODY TO THE ANTI-PROLACTIN RECEPTOR | 2013 |
|
RU2649372C2 |
| CONCENTRATED PROTEIN PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION | 2011 |
|
RU2626512C2 |
| ZINC-FREE AND ZINC-DEPLETED INSULIN COMPOSITIONS OF INCREASED STABILITY | 2002 |
|
RU2311922C2 |
| LIQUID COMPOSITION OF LONG-ACTING ALPHA INTERFERON CONJUGATE | 2011 |
|
RU2613905C2 |
| WATER-BASED HFSH COMPOSITIONS | 2006 |
|
RU2407514C2 |
| LIQUID PHARMACEUTICAL COMPOSITION | 2015 |
|
RU2719431C2 |
